Skip to Main Content
Contribute Try STAT+ Today

Good morning. Elizabeth Cooney here in Boston, sitting in for Ed Silverman, who’s on holiday this week. I’ll be queuing up the coffee (French roast) and some news items to start the day.

The U.K. has signed agreements to buy 90 million doses of vaccines in development by drugmakers including Pfizer (PFE), BioNTech (BNTX), and Valneva (VLA), joining countries around the world racing to secure supplies of protection against Covid-19, Bloomberg tells us. Britain, a nation of 66 million people, has already struck a supply agreement for a vaccine being tested by AstraZeneca (AZN) with the University of Oxford. Shares in AstraZeneca rose as much as 5.2% to a record in London ahead of news from a clinical trial due later today.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.